This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top analysts changed outlook on top names. See analyst ratings page for all changes.
Read original at benzingaStocks · News reference
Piper Sandler Reiterates Overweight on Definium Therapeutics, Raises Price Target to $75
Piper Sandler analyst David Amsellem reiterates Definium Therapeutics (NASDAQ:DFTX) with a Overweight and raises the price target from $73 to $75.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 7, 2026, 5:02 PM
- Checked
- Aug 7, 2026, 5:02 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
B of A Securities Initiates Coverage On Definium Therapeutics with Buy Rating, Announces Price Target of $75
B of A Securities analyst Tazeen Ahmad initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Buy rating and announces Price Target of $75.
Read original at benzingaMaxim Group Maintains Buy on Definium Therapeutics, Raises Price Target to $55
Maxim Group maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $50 to $55.
Read original at benzingaJones Trading Maintains Buy on Definium Therapeutics, Raises Price Target to $90
Jones Trading analyst Justin Walsh maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $74 to $90.
Read original at benzinga